沟通至关重要:COVID-19疫苗接种与妊娠的启示
孕妇感染COVID-19的发病率和死亡率高于非孕妇。随着真实世界证据表明孕期接种COVID-19疫苗未增加不良母婴结局风险,指南从个案获益-风险决策演变为2021年4月明确推荐孕期接种。疫苗犹豫阻碍接种,尤其年轻人和少数族裔;信任疫苗重要性、公共卫生机构及科学,加上良好沟通方法,是孕期接种的强预测因素。对卫生系统缺乏信任因初期知识空白和错误信息而加剧。医护人员应具备风险-获益沟通知识和技能,临床药理学家可评估药物警戒数据支持沟通。
要点
- 孕期接种COVID-19疫苗未增加不良母婴结局风险,指南已明确推荐孕期接种。
- 疫苗犹豫阻碍接种,信任和良好沟通是孕期接种的强预测因素。
- 医护人员应具备风险-获益沟通技能,临床药理学家可支持药物警戒数据评估。
核心结论
- 孕期接种COVID-19疫苗不增加不良母婴结局风险,指南已明确推荐孕期接种。
- 信任疫苗重要性、公共卫生机构和科学,以及良好沟通方法是孕期接种的强预测因素。
- 医护人员应具备风险-获益沟通知识和技能,临床药理学家可评估药物警戒数据支持沟通。
研究设计与样本
- 本文为综述,基于真实世界证据和指南演变,讨论COVID-19疫苗接种与妊娠的沟通问题。
主要发现
- 孕妇感染COVID-19的发病率和死亡率高于非孕妇。
- 真实世界证据表明孕期接种COVID-19疫苗未增加不良母婴结局风险。
- 疫苗犹豫在年轻人和少数族裔中更常见,孕妇有额外担忧。
- 对卫生系统缺乏信任因初期知识空白和错误信息而加剧,社交媒体加剧错误信息传播。
关键数值与推荐
- 指南于2021年4月明确推荐孕期接种COVID-19疫苗。
临床怎么用
- 医护人员应向孕妇提供COVID-19疫苗安全性的风险-获益沟通和 reassurance。
- 医护人员应接受科学沟通培训以更好提供风险-获益沟通。
- 临床药理学家应评估和综合新兴药物警戒数据,支持其他临床医生的风险-获益沟通。
- 信息应针对个体受众,考虑其观点和基础信仰体系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The morbidity and mortality from COVID-19 infection are higher in pregnant women compared to their nonpregnant counterparts. As real-world evidence accumulates demonstrating there is no increased risk of adverse maternal and neonatal outcomes associated with COVID-19 vaccination during pregnancy, guidelines have evolved from a case-by-case benefit-risk decision through to clear recommendation in April 2021 for COVID-19 vaccination in pregnancy. However, vaccine hesitancy is a barrier to uptake, especially among the younger population and individuals of ethnic minority backgrounds; pregnant women have additional concerns. Trust in the importance and effectiveness of the vaccine, trust in public health agencies and science, together with good communication methods regarding the safety of COVID-19 vaccines are strong factors for vaccination acceptance in pregnancy. Lack of trust in the health system was worsened by initial knowledge gaps in the information provided about COVID-19 infection and the safety and immunogenicity of COVID-19 vaccines. This was exacerbated by access to incorrect information and misinformation to fill in those knowledge gaps, especially with the increased use of social media. To provide advice and reassurance on COVID-19 vaccine safety to pregnant women, healthcare professionals involved in their care should have the knowledge and skills to provide risk-benefit communication and would benefit from access to training in science communication. Clinical pharmacologists have the expertise to appraise and synthesize emerging pharmacovigilance data, which can inform and support risk-benefit communication by other clinicians. Information should be strategically directed at individual audiences, taking their perspectives and foundational belief systems into consideration.
引用
- Cole C, Tsakiroglou M, Waitt C, et al. Communication is crucial: Lessons from COVID-19 vaccination and pregnancy. Br J Clin Pharmacol. 2022. PMID: 36321589. doi:10.1111/bcp.15578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。